Cysteine.

Glutathione is a tripeptide of cysteine, glycine and glutamate, and cysteine supply is the rate-limiting step while glycine is required for the second ligation. Supplying both amino acids gives the synthesis pathway the substrate it needs at each step.

Glutamine is converted to glutamate, the third amino acid in the glutathione tripeptide, so it completes the substrate set alongside cysteine and glycine. Cysteine remains the limiting input, which is why the two are formulated together rather than either alone.

Glutathione peroxidase enzymes carry selenium as selenocysteine at the active site and use glutathione as their reducing substrate. Cysteine feeds the glutathione pool while selenium supplies the enzyme itself, so the two sit on opposite ends of the same normal antioxidant cycle.

Cysteine breakdown passes through sulfite, which sulfite oxidase converts to sulfate using a molybdenum cofactor. Adequate molybdenum keeps that final step of normal sulfur amino acid handling running when cysteine intake is raised.

Ascorbate holds cysteine and glutathione in their reduced thiol state rather than as disulfides. Without it a larger share of dosed cysteine oxidises to cystine before it can be used.

Pyridoxal 5-phosphate is the cofactor for cystathionine beta-synthase and cystathionine gamma-lyase, the enzymes that make cysteine, and for cysteine sulfinate decarboxylase downstream. Cysteine handling in either direction depends on B6.

Cysteine is oxidised to cysteine sulfinate and decarboxylated to hypotaurine and then taurine. Supplying taurine directly leaves more cysteine for glutathione synthesis.

Cysteine is the limiting amino acid in glutathione synthesis, with glycine and glutamate rarely short. Dosing the tripeptide and its limiting precursor together loads the same pool from both ends.

Glutathione reductase is an FAD enzyme that returns oxidised glutathione to its reduced form. Riboflavin status decides how often each cysteine-derived glutathione molecule can be reused.

Dihydrolipoate reduces extracellular cystine to cysteine, which enters cells on a different and faster transporter than cystine does. That raises the intracellular pool available for glutathione synthesis.

Betaine donates a methyl group to homocysteine through BHMT, returning it to methionine instead of committing it down transsulfuration to cysteine. Supplemental cysteine covers the branch betaine diverts from.

B12-dependent methionine synthase remethylates homocysteine, competing with the transsulfuration route that produces cysteine. The two arms of the homocysteine branch point are handled together in practice.

5-methyltetrahydrofolate supplies the methyl group for remethylating homocysteine, the alternative to committing it to cysteine synthesis. Cysteine intake and folate status pull on opposite arms of one junction.

SAM-e is the methyl donor whose demethylation produces homocysteine and, through transsulfuration, cysteine. It also allosterically activates cystathionine beta-synthase, the committing enzyme of that route.

Cysteine-containing peptides reduce ferric to ferrous iron and keep it soluble at intestinal pH, part of the long-recognised meat factor. That raises non-heme iron uptake in the same way ascorbate does.

Metallothionein binds zinc through clusters of cysteine thiols, so cysteine supply is part of how zinc is buffered inside cells. Sulfur amino acid intake and zinc handling move together.

MSM is a small organic sulfur donor that adds to the sulfate and sulfur pool used in conjugation and connective tissue. It sits alongside cysteine rather than substituting for it, since only cysteine builds glutathione.

Free cysteine thiols reduce and chelate copper, forming complexes that lower the ion's availability in solution. Dosed in the same serving, a large thiol load can hold copper back.

Cysteine is conditionally essential precisely because the body can make it from methionine through the transsulfuration route. When methionine intake is low, cysteine becomes dietarily required; when cysteine intake is adequate, it spares methionine for methylation duty. The two amino acids trade off against each other in a defined and well-characterised way.

Serine supplies the carbon skeleton that cysteine is built on, while homocysteine supplies the sulfur. Without serine that condensation cannot happen and homocysteine has only the remethylation route left. This is a direct precursor relationship rather than a general nutritional pairing.

The two enzymes that convert homocysteine into cysteine both require pyridoxal-5-phosphate. Where that cofactor is short, homocysteine accumulates and endogenous cysteine production falls. Pyridoxal-5-phosphate is the already-phosphorylated form of the cofactor, which bypasses the pyridoxal kinase step.

Phosphopantothenoylcysteine synthetase joins cysteine to phosphopantothenate, and the cysteine-derived thiol is the business end of the finished coenzyme A molecule. Every acetyl and acyl transfer in metabolism runs through that thiol. This makes cysteine a structural precursor of a central metabolic cofactor, not just a glutathione input.

Whey proteins carry a high proportion of cystine and cysteine residues compared with most dietary proteins. Digestion releases those residues into the same cysteine pool that supports glutathione synthesis. Whey is the food-first route to the same substrate a cysteine supplement provides.

Sulforaphane raises the expression of the enzyme that combines cysteine with glutamate, the first step of glutathione synthesis. Cysteine supplies the substrate for that same enzyme. Raising enzyme capacity and raising substrate availability address different limits on the same pathway.

Silymarin's flavonolignans are studied for their effect on liver redox handling, including glutathione levels. Cysteine availability is what usually limits how much glutathione the liver can make. The pairing is mechanistically coherent and rests on separate literatures rather than a combination trial.

Homocysteine sits at a branch point: it can be remethylated back to methionine or committed forward to cysteine. Choline-derived betaine pushes the remethylation branch. Ample cysteine intake relieves the pull toward transsulfuration, so the two nutrients shape opposite sides of the same junction.

Alpha-tocopherol stops lipid chain reactions in membranes and is left as a radical that must be recycled. Ascorbate does that recycling and is itself restored using glutathione-linked reducing power. Cysteine sits at the base of that chain as the input that limits glutathione synthesis.

Guanidinoacetate methyltransferase uses a large share of the body's SAM to make creatine. Supplying creatine reduces that demand and leaves more methionine cycle capacity available. Since cysteine is made from methionine sulfur, the two nutrients interact through the same one-carbon economy.

Glutathione is a tripeptide of glutamate, cysteine and glycine, assembled in that order. Glutamate is the first partner cysteine is bonded to, through an unusual gamma-carboxyl linkage that protects the peptide from ordinary peptidases. Glutamate is rarely limiting, which is precisely why cysteine is the input that matters.

Zinc fingers and many metalloenzyme active sites are built from combinations of cysteine thiolates and histidine imidazoles coordinating a metal ion. Both amino acids also form soluble complexes with dietary minerals in the gut. This is structural biochemistry rather than a supplementation interaction.

The cysteine thiolate is a soft ligand that coordinates transition metals readily. Taken alongside a mineral, that binding changes the chemical species presented to the gut wall, in either direction depending on the metal. It is a formulation timing consideration, not a documented nutritional deficit.

Glutathione is only useful in its reduced form, and glutathione reductase needs NADPH to keep it there. That NADPH is built on a niacin-derived nicotinamide nucleotide. Supplying cysteine builds the glutathione pool; niacin-derived cofactors keep it reduced.